Surgery Partners SGRY
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Surgery Partners (SGRY) Business Model and Operations Summary
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It operates in two segments: Surgical Facility Services and Ancillary Services out of which the Surgical Facility Services segment accounts for the majority of revenue.
Key Insights
Surgery Partners (SGRY) Core Market Data and Business Metrics
Latest Closing Price
$23.48Market Cap
$3.00 BillionPrice-Earnings Ratio
-17.65Total Outstanding Shares
127.09 Million SharesTotal Employees
13,500Dividend
No dividendIPO Date
October 1, 2015SIC Description
Services-general Medical & Surgical Hospitals, NecPrimary Exchange
NASDAQHeadquarters
310 Seven Springs Way, Brentwood, TN, 37027
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $262 Million |
| Net Cash Flow From Financing Activities | $262 Million |
| Net Cash Flow From Operating Activities | $300.10 Million |
| Net Cash Flow From Investing Activities | $-488.50 Million |
| Net Cash Flow From Operating Activities, Continuing | $300.10 Million |
| Net Cash Flow From Investing Activities, Continuing | $-488.50 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Operating Expenses | $2.61 Billion |
| Income Tax Expense/Benefit, Deferred | $131.50 Million |
| Income/Loss From Equity Method Investments | $19.50 Million |
| Net Income/Loss Attributable To Parent | $-168.10 Million |
| Basic Earnings Per Share | $-1.33 |
| Income Tax Expense/Benefit | $134.60 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $-52.70 Million |
| Comprehensive Income/Loss Attributable To Parent | $-220.80 Million |
| Comprehensive Income/Loss | $-40.20 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $180.60 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Prepaid Expenses | $36.40 Million |
| Liabilities | $4.69 Billion |
| Long-term Debt | $3.40 Billion |
| Other Non-current Liabilities | $664.60 Million |
| Other Current Liabilities | $355.30 Million |
| Temporary Equity | $438.80 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||